Literature Share | Say Goodbye To Complex Purification? A Novel TFF + Surfactant Method Improves Efficiency And Reduces Costs in AAV Vector Production
Gene therapy is rapidly developing, yet its high cost remains a major barrier preventing broader patient access. Among the key drivers of this cost is the complex production process of adeno-associated virus (AAV) vectors. A study published in Biotechnology and Bioengineering has developed a novel purification method combining tangential flow filtration (TFF) with surfactants, which promises to simplify the AAV purification process and reduce costs. Let's delve into this research led by a team from the University of Tokyo.
1. Research Background: Challenges and Current Status of AAV Purification
AAV vectors have become "star" delivery tools in gene therapy due to their high safety, low immunogenicity, ability to infect both dividing and non-dividing cells, and capacity for long-term gene expression. However, their production process is complex, particularly the downstream purification steps, which typically involve multiple rounds of centrifugation and chromatography. These methods are time-consuming, labor-intensive, difficult to scale, and costly.
At laboratory scale, purification often relies on cesium chloride or iodixanol density gradient ultracentrifugation, which is challenging to scale for industrial production. Affinity chromatography is increasingly used, but the low pH elution conditions it requires can impair viral infectivity. Therefore, developing a simple, efficient, gentle, and scalable AAV purification method is critical.
Tangential flow filtration (TFF) is a size-based separation technique commonly used for concentrating and buffer-exchanging bioproducts. However, conventional TFF has limited ability to remove impurities such as host cell proteins (HCPs) and DNA during AAV purification, often leaving protein aggregates behind.
2. Innovative Approach: TFF Combined with Surfactants for Efficient Purification
To overcome the limitations of traditional TFF, researchers Rimi Miyaoka, Yuji Tsunekawa, and colleagues at the University of Tokyo devised a clever strategy: using surfactants to inhibit aggregation and interaction of impurity proteins, allowing them to pass through the TFF ultrafiltration membrane (500 kDa molecular weight cutoff) while retaining AAV viral particles (~25 nm in size).
They tested three types of surfactants:
- Non-ionic: Octyl glucoside
- Anionic: Sodium deoxycholate
- Zwitterionic: CHAPS
The study found that using a non-ionic surfactant alone was ineffective. Both the anionic sodium deoxycholate and zwitterionic CHAPS significantly enhanced removal of residual proteins, and they targeted different protein populations. Ultimately, combining 0.5% sodium deoxycholate with 1% CHAPS produced remarkable results, almost completely eliminating residual host proteins. SDS-PAGE analysis showed only the three clear AAV capsid protein bands (VP1/VP2/VP3).
Figure 1. TFF purification process without surfactants; (a) SDS-PAGE gel electrophoresis; (b) Transmission electron microscopy (TEM)
Figure 1. TFF purification process with surfactants;(a) SDS-PAGE gel electrophoresis;(b) Transmission electron microscopy (TEM)
3. Research Results: High Purity, Activity, and Safety
- Efficient impurity removal: The new method achieved 99.98% removal of HCPs and 95% removal of DNA, with purity comparable to or exceeding that of affinity chromatography.
- Improved infectivity: In vitro experiments showed that AAV1 vectors purified using this method infected HEK293 cells more efficiently than those purified by affinity chromatography (24.9% vs 20.8%), indicating better preservation of viral bioactivity.
- Good in vivo safety: Following local injection of purified AAV1 vectors into mouse skeletal muscle, no significant inflammation or tissue damage was observed after two weeks, demonstrating good in vivo safety.
- Broad serotype applicability: The method successfully purified multiple serotypes-including AAV1, AAV5, AAV8, and AAV9-from cell culture supernatants. However, for AAV2, which mainly exists in cell lysates with high impurity load, further optimization is needed.
4. Summary and Outlook
This study developed a simple, rapid (1.5 hours), efficient, and scalable new AAV purification process. By combining sodium deoxycholate and CHAPS, it successfully addressed the challenge of residual protein aggregation during TFF purification.
Advantages of the method include:
- Avoiding harsh low pH conditions, better preserving viral activity
- Reducing chromatography steps, simplifying the workflow, and saving time and costs
- Easily scalable, suitable for industrial large-scale production
- Providing a new strategy for purifying other biomacromolecules such as exosomes, other viruses, and recombinant antibodies
Current limitations include suboptimal viral recovery and inability to separate empty capsids from full viral particles, suggesting its best use may be as a first-step capture in a multi-step purification workflow.
In conclusion, this research offers an attractive new option for downstream AAV vector production and has the potential to significantly reduce the cost of gene therapy drugs, facilitating their broader application.
